LUPUS EUROPE PARTNERS

LE PARTNERS

LUPUS EUROPE PARTNERS

SLEuro is a voluntary association that promotes scientific research and information with regard to SLE and related syndromes. The Society is building a community of clinicians and researchers interested in SLE at an international level, promoting research and education on SLE as well as equal access to the best standards of care for SLE patients across Europe, and facilitating research projects and clinical trials in SLE.

LUPUS EUROPE is a strong supporter of SLEuro whose goals are fully aligned with LUPUS EUROPE’s vision of “A fulfilling life for all people with lupus in Europe until we have reached a world without lupus”. Over a number of years, we have appreciated the relentless efforts of the academics and researchers at the origin of SLEuro. We cannot thank them enough for their dedication to Lupus Research, the building-up of a dialogue with lupus patient groups, and their every day care for all people living with lupus in  Europe. To all lupus doctors, we say a big THANK YOU, from the depth of our hearts.

EPF: stands for the European Patients Forum. It is an umbrella organisation that represents European patients from all chronic disease areas. They work alongside their members in public health and health advocacy across Europe. Their members represent specific chronic disease groups at EU level or are national coalitions of patients. Their vision is that all patients with chronic and/or lifelong conditions in the EU have access to high quality, patient-centred equitable health and social care. Their mission is to ensure that the patients’ community drives policies and programmes that affect patients’ lives to bring changes empowering them to be equal citizens in the EU. They do this through educational seminars, policy initiatives and projects. LUPUS EUROPE is very involved in the work of EPF and tries to be present in all relevant seminars and projects.

EULAR: stands for European League Against Rheumatism and is a pan European organisation for healthcare professionals, scientific societies and national patient organisations (see PARE), specifically for rheumatic diseases. EULAR’s aim is to reduce the burden of rheumatic diseases on the individual and society and to improve the treatment, prevention and rehabilitation of musculoskeletal diseases.

The EULAR Annual European Congress of Rheumatology is held once a year (usually in June) in alternating major cities around Europe. It is seen as the primary platform for exchange of scientific and clinical information in Europe. It is also a renowned forum for interaction between medical doctors, scientists, people with arthritis/rheumatism, health professionals and representatives of the pharmaceutical industry worldwide. LUPUS EUROPE is always represented.

IAPO: stands for The International Alliance of Patients’ Organizations and is a global alliance representing patients of all nations across all disease areas.

PARE: stands for People with Arthritis/Rheumatism in Europe and consists of national rheumatic patient organisations across Europe. They focus on actively involving people with arthritis/musculoskeletal conditions and encouraging them to take on a leading role in activities and projects that benefit their wider community. The Annual European Conference of PARE is held once a year in cities around Europe. Here representatives of the national rheumatism organisations have a chance to network with each other, get inspired and learn new things through workshops, lectures and networking events. LUPUS EUROPE is always represented.

SLEuro is a voluntary association that promotes scientific research and information with regard to SLE and related syndromes. The Society is building a community of clinicians and researchers interested in SLE at an international level, promoting research and education on SLE as well as equal access to the best standards of care for SLE patients across Europe, and facilitating research projects and clinical trials in SLE.

LUPUS EUROPE is a strong supporter of SLEuro whose goals are fully aligned with LUPUS EUROPE’s vision of “A fulfilling life for all people with lupus in Europe until we have reached a world without lupus”. Over a number of years, we have appreciated the relentless efforts of the academics and researchers at the origin of SLEuro. We cannot thank them enough for their dedication to Lupus Research, the building-up of a dialogue with lupus patient groups, and their every day care for all people living with lupus in  Europe. To all lupus doctors, we say a big THANK YOU, from the depth of our hearts.

EPF: stands for the European Patients Forum. It is an umbrella organisation that represents European patients from all chronic disease areas. They work alongside their members in public health and health advocacy across Europe. Their members represent specific chronic disease groups at EU level or are national coalitions of patients. Their vision is that all patients with chronic and/or lifelong conditions in the EU have access to high quality, patient-centred equitable health and social care. Their mission is to ensure that the patients’ community drives policies and programmes that affect patients’ lives to bring changes empowering them to be equal citizens in the EU. They do this through educational seminars, policy initiatives and projects. LUPUS EUROPE is very involved in the work of EPF and tries to be present in all relevant seminars and projects.

EULAR: stands for European League Against Rheumatism and is a pan European organisation for healthcare professionals, scientific societies and national patient organisations (see PARE), specifically for rheumatic diseases. EULAR’s aim is to reduce the burden of rheumatic diseases on the individual and society and to improve the treatment, prevention and rehabilitation of musculoskeletal diseases.

The EULAR Annual European Congress of Rheumatology is held once a year (usually in June) in alternating major cities around Europe. It is seen as the primary platform for exchange of scientific and clinical information in Europe. It is also a renowned forum for interaction between medical doctors, scientists, people with arthritis/rheumatism, health professionals and representatives of the pharmaceutical industry worldwide. LUPUS EUROPE is always represented.

IAPO: stands for The International Alliance of Patients’ Organizations and is a global alliance representing patients of all nations across all disease areas.

PARE: stands for People with Arthritis/Rheumatism in Europe and consists of national rheumatic patient organisations across Europe. They focus on actively involving people with arthritis/musculoskeletal conditions and encouraging them to take on a leading role in activities and projects that benefit their wider community. The Annual European Conference of PARE is held once a year in cities around Europe. Here representatives of the national rheumatism organisations have a chance to network with each other, get inspired and learn new things through workshops, lectures and networking events. LUPUS EUROPE is always represented.

LUPUS EUROPE SPONSORS

LUPUS EUROPE is run by a board consisting of eight members (six volunteers and two contractors providing  part-time paid secretariat), as well as co-opted volunteers as needed.

Unfortunately, LUPUS EUROPE cannot rely on public funding to run its activities. We therefore have to operate based on grants or donations from sponsors. In 2022, we have received support from industry for a total amount of 76.4% of our total budget. Non Pharma income has accounted for 23.5% of the total, with academics contributing 1.7%, volunteers 20.9%, and members 0.7%.

In our relations with industry, we rely on  the EFPIA Codes of Practice on relationships between the Pharmaceutical industry and patient organisations / healthcare professionals. We are particularly careful not to depend on any  single industry representative, and have fixed a target maximum contribution from a single firm to 20% of our budget. In 2022 the highest contribution of a single company has been 10.3% of our total budget.

Over the past year, LUPUS EUROPE has received support from the following partners and sponsors:

Logo of Bristol Myers Squibb in black writing with a purple hand image at the beginning

LUPUS EUROPE also enjoyed donations in kind from

Live Facebook Feed

Comments Box SVG iconsUsed for the like, share, comment, and reaction icons

🦋 EULAR started yesterday!

This year, #EULAR2026 brings together a huge rheumatology community:

📊 5,705 abstracts submitted from 102 countries, a new EULAR record
📊 187 scientific sessions across 15 tracks
📊 More than 350 distinguished speakers from 43 nations

And Lupus Europe is here!

As promised, some of our PAN members are covering lupus-related sessions to bring key messages back to the lupus community.

🧑‍🤝‍🧑 One of yesterday’s highlights was seeing Marina Pietri present our poster on Sex & Lupus co-creation, with Rita Vieira also there representing the Youth Group’s work. The poster shows how young people with lupus worked with a clinician to create a safe, respectful space to talk about sex, intimacy and lupus, topics that are still too often left out of routine care.

A big thank you to Dr Cristiana Sieiro Santos for her support and collaboration in making this work possible.

🎥 If you haven’t watched the webinar yet, visit our YouTube channel and watch it there.

🧠 We also followed a session on fatigue, one of the symptoms people with lupus most often report as difficult to explain, measure and manage. The session looked at when tiredness becomes pathological, how fatigue can be assessed, and why lifestyle advice needs to be realistic and adapted to each person.

💬 Patient-doctor communication was another key topic yesterday. Have you heard about the Lupus Consultation Cards? Inspired by the work of NVLE in collaboration with ERN ReCONNET, they are a simple tool to help people prepare for appointments, organise symptoms and questions, and focus the conversation on what matters most. This is the idea behind our #MakeItCount campaign.

🌍 Dr Daniel Guimarães de Oliveira presented a poster on social determinants of health in lupus care, co-authored with our General Secretary Zoe Karakikla Mitsakou. This work shows how healthcare professionals, Patient Research Partners from Lupus Europe, local patient volunteers and social workers co-designed a practical framework to identify barriers such as financial pressure, health literacy, transport, social support and access to care, and connect them with local solutions.

📱 Digital tools were also part of yesterday’s programme, with discussions on how technology can support self-management, shared decision-making and patient empowerment. For Lupus Europe, this strongly connects with our work on reliable, patient-centred digital information, including #LupusGPT and #EasyLupus.

🔬 We also followed the session “The mitochondria: a new culprit for autoimmune diseases?”. The discussion explored how mitochondrial DNA and RNA may act as danger signals, activating immune pathways such as interferon responses and contributing to inflammation in lupus and other autoimmune diseases.

👏 Kudos to our PAN members and Board members for their great job on this first day of EULAR!

🦋 Stay tuned. Today will be another big day for Lupus Europe at #EULAR2026!

Our Chair, Jeanette Andersen, will speak in the session on non-pharmacological interventions to improve quality of life.

We also have a Meet the EULAR Expert session on “AI as a Partner in Care: Empowering the RMD Community with Information”, focusing on AI tools such as #LupusGPT and #EasyLupus, which will be delivered by Zoe Karakikla Mitsakou.
... See MoreSee Less

Image attachment
Image attachment
Image attachment
Image attachment
Image attachment

☀️ Good morning from beautiful London!

#Eular2026 is here, and so are we‼️

💬 You may already know #lupusgpt. You may have read the paper in The Lancet Rheumatology. You may have tried the tool, shared it with a patient, or recommended it to a colleague.

📊 But there is more. More to do. More lessons learned from two years of building something genuinely patient-led. More to understand about what happens when patients, clinicians, and AI specialists work together from the very first question.

🦋 This week, we will be sharing it all.

#lupusgpt: more than you think. Further than you imagined.
... See MoreSee Less

☀️ Good morning

📅 Tomorrow, the EULAR Congress begins!

🌍 #Eular2026 starts tomorrow, and Lupus Europe will be there!

🦋 We will be representing the patient voice, following the latest research, and sharing key updates with our community throughout the week.

Stay tuned for live updates, session highlights, and much more.

💬 Will you be following the congress? Let us know in the comments!
... See MoreSee Less

📅 Tomorrow, the E

🔴 𝐑𝐞𝐦𝐢𝐬𝐬𝐢𝐨𝐧 𝐝𝐨𝐞𝐬𝐧❜𝐭 𝐚𝐥𝐰𝐚𝐲𝐬 𝐟𝐞𝐞𝐥 𝐥𝐢𝐤𝐞 𝐫𝐞𝐦𝐢𝐬𝐬𝐢𝐨𝐧 🔴

This is one of the most important insights from a new editorial just published in Rheumatology.

📋 The editorial responds to a study analysing five years of data from the Amsterdam SLE cohort. The findings are striking:

🔹 In over half of clinical visits, patients rated their disease as more active than their physicians did.
🔹 Even among visits meeting formal remission criteria, more than 1 in 3 patients still reported significant disease burden.

These discrepancies highlight an important gap between how disease activity is measured clinically and how lupus is experienced by patients in daily life

📊 According to LUPUS EUROPE’s Swiss Knife Survey, patients’ definitions of “disease control” often go far beyond normal blood tests. They include 𝗳𝗿𝗲𝗲𝗱𝗼𝗺 𝗳𝗿𝗼𝗺 𝗳𝗹𝗮𝗿𝗲𝘀, 𝘀𝘁𝗮𝗯𝗹𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁, 𝗾𝘂𝗮𝗹𝗶𝘁𝘆 𝗼𝗳 𝗹𝗶𝗳𝗲, and the ability 𝗹𝗶𝘃𝗲 𝗮𝘀 𝗻𝗼𝗿𝗺𝗮𝗹𝗹𝘆 𝗮𝘀 𝗽𝗼𝘀𝘀𝗶𝗯𝗹𝗲.

𝗦𝗵𝗮𝗿𝗲 𝘄𝗶𝘁𝗵 𝘂𝘀 𝘄𝗵𝗮𝘁 𝗿𝗲𝗺𝗶𝘀𝘀𝗶𝗼𝗻 𝗺𝗲𝗮𝗻𝘀 𝗳𝗼𝗿 𝘆𝗼𝘂. Let's make it visible.

The editorial, co-authored by Dr Alvaro Gomez from Karolinska Institutet, and Zoe Karakikla-Mitsakou, LUPUS EUROPE General Secretary, points to several possible ways this might be addressed:

✅ Incorporating patient-reported outcomes into treatment target definitions
✅ Using assessment tools that better integrate patient-reported symptoms
✅ Exploring broader target frameworks that better reflect what meaningful disease control may look like for people living with lupus

This reinforces why people with lupus must be involved from the start in shaping how treatment success is defined, measured, and pursued.

💬 Have you ever been told you are in remission but not felt like it?

Share what remission means for you in the comments. Let’s make it visible.

📖 Read the full editorial: doi.org/10.1093/rheumatology/keag259
... See MoreSee Less